Claritas Pharmaceuticals, Inc. Share Price

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

OTC Markets Traded
Market Closed - 10:46:04 27/02/2026 pm IST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Claritas Pharmaceuticals, Inc. -.--% -

Valuation : Claritas Pharmaceuticals, Inc.

Market Cap 53.68L 38.64L 33.3L 31.22L 28.5L 37Cr 53.86L 3.7Cr 1.45Cr 19Cr 1.45Cr 1.42Cr 62Cr P/E 2019
-0.74x
P/E 2020 0.13x
Enterprise Value 62.88L 45.26L 39L 36.57L 33.38L 43Cr 63.08L 4.34Cr 1.69Cr 22Cr 1.7Cr 1.66Cr 72Cr EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
99.74%
Yield 2019 *
-
Yield 2020 -
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.4
10 years 0
Extreme 1.0E-6
15.31
Manager TitleAgeSince
Chief Executive Officer 76 21/06/2017
Director of Finance/CFO 58 29/06/2018
Director TitleAgeSince
Chairman 76 18/03/2021
Date Insider Type Main position Quantity % Market Cap.
11/10/21 Buy 1,18,000 0.3332%
11/10/21 Buy 1,52,500 0.4307%
11/10/21 Buy 24,500 0.0692%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 37
-0.78%-1.42%+2.49%+22.78% 5.11TCr
-6.00%-0.75%+442.41%+544.39% 4.74TCr
-0.24%+0.74%+38.69%+18.02% 4.32TCr
-1.55%-2.07%+23.08%+81.47% 4.24TCr
-0.31%-0.83%+16.15%+51.42% 3.32TCr
-1.79%-3.24%+27.00%+129.56% 1.71TCr
-0.58%-2.12% - - 1.64TCr
-0.88%-0.66%+11.60%+27.75% 1.48TCr
-1.66%-1.25%+78.59%+46.66% 1.42TCr
Average -1.38%+0.06%+80.00%+115.26% 2.8TCr
Weighted average by Cap. -1.74%+0.35%+98.85%+137.44%

Financials

2019 2020
Net sales - -
Net income -2.12Cr -1.53Cr -1.32Cr -1.23Cr -1.13Cr -145.92Cr -2.13Cr -15Cr -5.71Cr -74Cr -5.73Cr -5.61Cr -244.23Cr 42.1L 30.3L 26.11L 24.48L 22.35L 29Cr 42.23L 2.9Cr 1.13Cr 15Cr 1.14Cr 1.11Cr 48Cr
Net Debt 7L 5L 4L 4L 4L 4.84Cr 7L 48.57L 18.95L 2.44Cr 19.02L 18.61L 8.11Cr 9L 7L 6L 5L 5L 6.33Cr 9L 63.47L 24.76L 3.19Cr 24.86L 24.32L 11Cr
Logo Claritas Pharmaceuticals, Inc.
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. CLAZF Stock